Alebund Pharmaceuticals (Jiangsu) Limited, which is scheduled to list 56.76 million H shares on the Hong Kong Main Board on 29 June 2026 (CSRC filing date: 24 April 2026), released its updated Articles of Association outlining capital structure, shareholder composition and corporate-governance arrangements.
Capital & Share Structure • Registered capital: RMB348.37 million, divided into 348.37 million ordinary shares with a par value of RMB1 each. • Pre-listing conversion: RMB712.98 million of audited net assets from Alebund Biopharmaceuticals (Jiangsu) Co., Ltd. were converted into 258.00 million shares at a 1:0.3619 ratio; the RMB454.98 million surplus was credited to capital reserve. • H-share tranche: 56.76 million shares will trade in Hong Kong; existing unlisted shares may be converted to H shares without shareholder voting, subject to regulatory procedures. • Promoter holdings: AleyuanGX Limited (4.89%), Yangzhou Liyue Consulting Management Partnership (8.19%) and Guangxi Tencent Venture Capital Co., Ltd. (8.52%) are the three largest founding shareholders.
Share Issuance, Repurchase & Transfer • Future capital increases may be executed via public or targeted share issues, bonus shares or reserve conversions. • Share buy-backs are capped at 10% of issued capital and are limited to six-month or three-year holding periods depending on purpose. • Pre-IPO shares are locked up for 12 months post-listing; directors and senior management face additional sale restrictions.
Governance Structure • Board composition: Eight directors, including a chairman and at least three independent non-executive directors. • Audit Committee: Three members (minimum two independent directors) assume statutory supervisory responsibilities. • Other committees: Strategy, Nomination, and Remuneration & Appraisal Committees, each with three members. • Senior management positions include a general manager, chief medical officer, chief operating officer and chief financial officer.
Profit Distribution Policy • A minimum 10% of annual post-tax profit is allocated to statutory reserve until it reaches 50% of registered capital. • The company targets stable and sustainable dividends, with cash distribution prioritised once statutory conditions are met. • Dividend payment or share allotment must be completed within two months after shareholder approval.
Business Scope & Objectives Alebund focuses on addressing unmet clinical needs in kidney and other chronic diseases through advanced scientific technologies, aiming for long-term value creation for patients and shareholders.
Audit & Internal Control • The company will appoint an accounting firm annually, subject to shareholder approval. • A standalone internal-audit function, overseen by the Audit Committee, will prepare annual internal-control evaluation reports.
The Articles, effective upon registration, supersede previous versions and may be amended by a two-thirds majority vote at the general meeting, ensuring continued compliance with PRC law and Hong Kong Listing Rules.